However, it is important to underline that this study was carried out on a different population of Chinese patients, who mainly had localized colon cancer, and NGS was performed only on primary tumor tissue and in a very different molecular landscape (e.g., 59% with TP53 mutation in our study vs. 74% in Gao et al.). This evidence concerns the gene TP53 and malignant colon neoplasm.